Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2000
11/23/2000WO2000070076A1 Tm4sf receptors
11/23/2000WO2000070051A1 NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
11/23/2000WO2000070049A2 Extracellular signaling molecules
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070046A2 Secreted polypeptides and corresponding polynucleotides
11/23/2000WO2000070045A1 Ox2 receptor homologs
11/23/2000WO2000070042A1 143 human secreted proteins
11/23/2000WO2000070036A2 Genes expressed in hippocampus
11/23/2000WO2000070028A1 Sphingosine kinase enzyme
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000069900A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
11/23/2000WO2000069884A2 Compositions isolated from skin cells and methods for their use
11/23/2000WO2000069861A1 THIAZOLOPYRIMIDINES USEFUL AS TNFα INHIBITORS
11/23/2000WO2000069859A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/23/2000WO2000069858A1 Imidazodiazepine derivative
11/23/2000WO2000069848A1 Compounds having cytokine inhibitory activity
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069846A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069836A1 Short-acting benzodiazepines
11/23/2000WO2000069831A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
11/23/2000WO2000069829A1 Method of inhibiting neurotrophin-receptor binding
11/23/2000WO2000069828A1 Method of inhibiting neurotrophin-receptor binding
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069823A1 Ion channel modulating agents
11/23/2000WO2000069821A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069819A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000WO2000069818A1 MORPHOLINO-N-ETHYL ESTER DERIVATIVE OF AN INDOLE sPLA2 INHIBITOR
11/23/2000WO2000069472A2 Enzyme-activated anti-tumor prodrug compounds
11/23/2000WO2000069464A1 Novel use
11/23/2000WO2000069456A2 Adjuvant combination formulations
11/23/2000WO2000069448A1 Bone marrow transplantation for treatment of stroke
11/23/2000WO2000069444A1 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia
11/23/2000WO2000069442A1 Methods of making and using n-desmethylzopiclone
11/23/2000WO2000069440A2 Nicotine delivery systems
11/23/2000WO2000069424A2 Method of treating psychotic disorders
11/23/2000WO2000069412A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
11/23/2000WO2000069262A1 NOVEL β-SECRETASE AND MODULATION OF β-SECRETASE ACTIVITY
11/23/2000WO2000069257A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000037685A9 Method of identifying a psychotropic agent using differential gene expression
11/23/2000WO2000033812A3 Transdermal patch for delivering volatile liquid drugs
11/23/2000WO2000031124A3 Peptides that modulate the interaction of b class ephrins and pdz domains
11/23/2000WO2000026348A3 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
11/23/2000WO2000023059A3 Use of anticonvulsant derivatives for treating alcohol dependency
11/23/2000WO2000023053A3 Artificial antigen-specific cells and related methods
11/23/2000WO2000020450A3 Calcium channel alpha-2/delta gene
11/23/2000WO2000017369A3 Alzheimer's disease secretase
11/23/2000WO1999048482A3 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
11/23/2000WO1999045952A3 Method of preventing the death of retinal neurons and treating ocular diseases
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000DE19923086A1 New cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, are ATP-sensitive potassium channel inhibitors and vagal nervous system stimulants useful for treating cardiovascular disorders
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000CA2767116A1 Adjuvant combination formulations
11/23/2000CA2623458A1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
11/23/2000CA2505617A1 Modified secretin and method of synthesizing thereof
11/23/2000CA2499211A1 Modified peptides yy and conjugates thereof
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2373975A1 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia
11/23/2000CA2373855A1 Method of treating psychotic disorders
11/23/2000CA2373697A1 Method of inhibiting neurotrophin-receptor binding
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373616A1 Tm4sf receptors
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373532A1 Morpholino-n-ethyl ester derivative of an indole spla2 inhibitor
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373416A1 Method of inhibiting neurotrophin-receptor binding
11/23/2000CA2373231A1 Extracellular signaling molecules
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372429A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2372044A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2370066A1 Thiazolopyrimidines useful as tnf.alpha. inhibitors
11/23/2000CA2368833A1 Molecules expressed in hippocampus
11/23/2000CA2368624A1 Novel .beta.-secretase and modulation of .beta.-secretase activity
11/23/2000CA2368620A1 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/22/2000EP1053748A1 Remedies for neurological disorders
11/22/2000EP1053341A1 Use of negative regulation elements for nerve-specific expression of transgenes
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053244A1 Glycosidation of 4,5-epoxymorphinan-6-ols
11/22/2000EP1053238A1 Therapeutic compounds
11/22/2000EP1053236A1 Pyrdiyl-briidgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
11/22/2000EP1053235A1 Oxazole derivatives as serotonin-1a receptor agonists
11/22/2000EP1053234A1 Salts of paroxetine
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053226A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
11/22/2000EP1053014A1 BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE
11/22/2000EP1053007A2 Methods and compositions for modulating leptin activity
1 ... 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 ... 1833